2020 Help me understand this report
A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISE
Search citation statements
Paper Sections
Select...
1
Citation Types
0
1
0
Year Published
2022
2022
Publication Types
Select...
1
Relationship
0
1
Authors
Journals
Cited by 1 publication
(1 citation statement)
References 0 publications
0
1
0
“…The most common adverse event in all groups was fatigue; it has occurred in up to 20% of patients. (49).…”
Section: Sequencing Treatment Lines In Patients With Mcrpcmentioning
confidence: 99%
“…The most common adverse event in all groups was fatigue; it has occurred in up to 20% of patients. (49).…”
Section: Sequencing Treatment Lines In Patients With Mcrpcmentioning
confidence: 99%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
